Modulation of Cerebral Blood Flow Using Iron Chelators

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is determine if the iron chelator, desferrioxamine can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Brigham and Women's Hospital
• Collaborator: National Institute on Aging (NIA)
• Treatments: Deferoxamine

Criteria

Inclusion Criteria:

• healthy adults between the ages of 18-80 years.

Exclusion Criteria:

• subjects taking vasoactive medications,

• hypertension,

• pregnant women, smokers,

• COPD,

• asthma,

• diabetes mellitus,

• intracranial or carotid stenosis,

• hepatic disease,

• renal disease,

• bone marrow suppression,

• cardiac disease,

• heart failure,

• iron deficiency,

• history of cancer,

• history of head trauma,

• subarachnoid hemorrhage,

• central nervous system vasculitis,

• multiple sclerosis,

• migraines,

• seizures,

• sickle cell disease or trait,

• cardiac arrhythmia,

• unable to give informed consent, or

• poor transcranial Doppler insonation windows.